Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 11/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13044271 | 0.90 | KMT2A (0.51) | CSF1RNPC1RAB9AMEN1KMT2A | |
| SCHEMBL13552668 | 0.87 | USP28 (0.47) | CSF1RNPC1RAB9AMEN1KMT2A | |
| SCHEMBL13552857 | 0.87 | NPC1 (0.61) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13552712 | 0.87 | CSF1R (0.47) | CSF1RNPC1RAB9ACYP11B2MEN1 | |
| SCHEMBL13044263 | 0.86 | MEN1 (0.48) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL13552709 | 0.86 | USP28 (0.46) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13552995 | 0.86 | MEN1 (0.54) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL13552661 | 0.85 | NAMPT (0.43) | CSF1RNPC1RAB9AMEN1KMT2A | |
| SCHEMBL13044260 | 0.85 | PTGES (0.42) | CSF1RNPC1RAB9AMEN1KMT2A | |
| SCHEMBL13044261 | 0.85 | USP28 (0.45) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9345699-B2 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | NANTBIOSCIENCE, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9345699-B2 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | NANTBIOSCIENCE, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2440048-B1 | ISOQUINOLINE, QUINOLINE, AND QUINAZOLINE DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING | CALIFORNIA CAPITAL EQUITY LLC (US) | 2015-10-07 | — | — | EP | disclosed |
| US-20140072630-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140072630-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130045240-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045240-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2013-02-21 | — | — | US | disclosed |
| US-20120270858-A1 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270858-A1 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-10-25 | — | — | US | disclosed |
| WO-2010144586-A1 | ISOQUINOLINE, QUINOLINE, AND QUINAZOLINE DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045240-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | SHH, GLI1, SMO | CSF1R 580/4885NPC1 169/4885RAB9A 367/4885 |
| US-20120270858-A1 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | SHH, GLI1, SMO | CSF1R 402/4885NPC1 1532/4885RAB9A 447/4885 |
| US-20140072630-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | SHH, GLI1, SMO | CSF1R 580/4885NPC1 169/4885RAB9A 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.